Ruxolitinib In Combination With Capecitabine Has Successful Phase 2 Pancreatic Cancer Trial.

The Wall Street Journal (8/21, Rubin, Subscription Publication, 5.33M) reports that Incyte’s ruxolitinib taken in combination with capecitabine improved six-month survival in patients with recurrent or treatment refractory metastatic pancreatic cancer by 42%, compared to 11% for a placebo. CEO Paul A. Friedman explains the successful Phase 2 trials show that “JAK inhibition is active in this disease.” The company is seeking to enter Phase 3 trials to help “a population with no attractive treatment options.”

        Bloomberg News (8/22, Edney, 1.41M) reports that ruxolitinib has had FDA approval for treating leukemia since 2011. The trial is the first to show that solid tumors can be impacted by the JAK inhibitor class of medications.

        The AP (8/21) reports that ruxolitinib helps myelofibrosis patients by reducing spleen swelling.

        Reuters (8/21) reports that the treatment group in the trial only had a 12% discontinued rate for adverse events, while people who received the capecitabine chemotherapy alone had a 20% dropout rate


Captavi QixSuite™ - Hosted Marketing Automation Software ©